Entrada Therapeutics (TRDA) Non Operating Income (2020 - 2026)

Entrada Therapeutics has reported Non Operating Income for 7 years, with the latest figure at $2.6 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 40.91% year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at $13.3 million (down 32.72% YoY), and the FY2025 full-year result was $15.1 million, down 22.6% from the prior year.
• Non Operating Income for Q1 2026 stood at $2.6 million, down from $3.1 million in the prior quarter.
• The five-year high for Non Operating Income was $5.8 million in Q3 2024, with the low at $403000.0 in Q2 2022.
• Average Non Operating Income over 5 years is $3.2 million, with a median of $3.9 million recorded in 2025.
• Year-over-year, Non Operating Income surged 7207.69% in 2022 and tumbled 40.91% in 2026.
• Tracing TRDA's Non Operating Income over 5 years: stood at $950000.0 in 2022, then surged by 351.79% to $4.3 million in 2023, then climbed by 19.48% to $5.1 million in 2024, then sank by 38.85% to $3.1 million in 2025, then retreated by 16.33% to $2.6 million in 2026.
• The last three Non Operating Income figures came in at $2.6 million (Q1 2026), $3.1 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.

Peer Comparison